What’s Happening in the 2026 Bundibugyo Ebola Outbreak in Congo and Uganda

The outbreak began in Ituri Province in northeastern DRC, particularly in the Mongbwalu health zone, where officials were first alerted on May 5 to a cluster of severe illness with high mortality, including deaths among health workers. Laboratory testing confirmed Bundibugyo virus disease around May 14–15.

Cases linked to the outbreak have also been identified outside the initial area, including:

• Imported infections in Kampala, Uganda
• At least one reported case in Kinshasa, the DRC capital

These detections show both cross‑border and long‑distance spread, increasing the risk of further regional transmission.

Why the WHO Declared an International Emergency

On May 17, 2026, the WHO determined that the outbreak met the criteria for a Public Health Emergency of International Concern, a formal alert used for the most serious international health threats.

Several factors drove the decision:

• Cross‑border transmission: confirmed spread from the DRC into Uganda.
• Uncertain scale: weak surveillance means the true number of infections may be higher.
• High fatality risk: past Bundibugyo outbreaks have shown case‑fatality rates around 30–50%.
• Lack of medical countermeasures: there are no approved vaccines or treatments for this Ebola species.
• Health‑system vulnerability: outbreaks in conflict‑affected regions are harder to contain.

The declaration is meant to mobilize funding, international coordination, and emergency response teams. Importantly, WHO said the situation does not meet the criteria for a pandemic emergency, and broad travel bans are not recommended.

Why Existing Ebola Vaccines May Not Work

Most modern Ebola countermeasures were developed after the large West African Ebola epidemic (2014–2016) and target Zaire ebolavirus, the species responsible for most major outbreaks.

The current outbreak is caused by Bundibugyo ebolavirus, which is genetically distinct. That difference means existing vaccines were not designed to protect against it.

Regulators and health agencies note that:

• No authorised vaccine exists specifically for Bundibugyo virus disease.
• Licensed Ebola vaccines such as Ervebo were built to protect against the Zaire species.

Scientists are debating whether the Zaire vaccine might offer partial cross‑protection, but the evidence is limited and uncertain.

Why Available Treatments May Not Work

Similarly, the two licensed monoclonal‑antibody treatments for Ebola — used successfully in recent outbreaks — were also designed for the Zaire strain.

Experts say there are no approved antiviral treatments for Bundibugyo virus disease, leaving clinicians largely limited to supportive medical care.

Typical treatment therefore focuses on:

• Rehydration and electrolyte balance
• Stabilizing blood pressure and oxygen levels
• Managing complications
• Strict infection‑control measures

Supportive care can improve survival, but it does not directly target the virus.

How Far Away a Bundibugyo Vaccine Is

A vaccine specifically targeting the Bundibugyo strain is not yet ready for human trials.

Health experts say candidate vaccines would still need additional laboratory work and animal testing before clinical trials could begin. Estimates suggest it could take many months before a candidate is ready for human testing.

In response to the outbreak, WHO convened expert groups to evaluate whether:

• experimental vaccines could be accelerated
• existing Ebola vaccines might be used experimentally
• new candidates could move rapidly into trials

But for now, no Bundibugyo‑specific vaccine is available for outbreak control.

Why Controlling This Outbreak Is Difficult

Several structural factors are complicating the response.

1. Delayed detection

The outbreak likely circulated for some time before confirmation. Authorities were alerted to unusual deaths on May 5, but the virus species was confirmed only about nine days later after laboratory analysis.

That delay allows transmission chains to grow before contact tracing and isolation begin.

2. Weak diagnostics and surveillance

Because Bundibugyo outbreaks are rare, fewer specialized diagnostic tools and preparedness plans exist compared with the more common Zaire strain. This makes early identification harder and suspected case counts less reliable.

3. Conflict and limited access

Eastern DRC has long‑running insecurity. Conflict can restrict access for surveillance teams, laboratories, safe‑burial teams, and community outreach, allowing hidden transmission to continue.

4. Cross‑border spread

With cases appearing in Uganda as well as the DRC, the response must be coordinated across national borders with shared surveillance, contact tracing, and laboratory confirmation.

What the Global Risk Looks Like

Health authorities say the highest risk remains in the DRC, Uganda, and neighboring countries with strong travel links and vulnerable health systems.

The broader international risk is currently considered low, especially if cases are detected quickly and isolated.

The central concern is not that the virus has become pandemic‑capable, but that the world lacks proven vaccines and treatments for this Ebola species while the outbreak is already spreading across borders.

That combination — a rare virus, limited tools, and challenging conditions on the ground — is why global health agencies are treating the outbreak as a major international emergency.